Molecular structure of Aurora Kinase/Cdk Inhibitor, CAS Number: 443797-96-4
Aurora Kinase/Cdk Inhibitor (CAS 443797-96-4)
Alternate Names:
JNJ-7706621, 4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide
Application:
Aurora Kinase/Cdk Inhibitor is (JNJ-7706621) a cell-permeable, reversible, ATP-competitive kinase inhibitor
CAS Number:
443797-96-4
Purity:
≥97%
Molecular Weight:
435.4
Molecular Formula:
C15H12F2N6O3S•CH3CN
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Aurora Kinase/Cdk Inhibitor is a cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC50 = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk′s (IC50 = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties (IC50 in the range of 112 - 514 nM against various human cancer cell lines) and in a xenograft murine model (75-100 mg/kg, i.p.).
Aurora Kinase/Cdk Inhibitor (CAS 443797-96-4) References
- 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. | Lin, R., et al. 2005. J Med Chem. 48: 4208-11. PMID: 15974571
- The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. | Emanuel, S., et al. 2005. Cancer Res. 65: 9038-46. PMID: 16204078
- Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. | Huang, S., et al. 2006. Bioorg Med Chem Lett. 16: 3639-41. PMID: 16682186
- Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. | Seamon, JA., et al. 2006. Mol Cancer Ther. 5: 2459-67. PMID: 17041089
- Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621. | Danhier, F., et al. 2010. Int J Pharm. 392: 20-8. PMID: 20226846
- Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases. | Matsuhashi, A., et al. 2012. Curr Cancer Drug Targets. 12: 625-39. PMID: 22463590
- Identification of Driver Genes and Key Pathways of Glioblastoma Shows JNJ-7706621 as a Novel Antiglioblastoma Drug. | Zhong, S., et al. 2018. World Neurosurg. 109: e329-e342. PMID: 28989042
- The cyclin-dependent kinase inhibitor, JNJ-7706621, improves in vitro developmental competence of porcine parthenogenetic activation and somatic cell nuclear transfer embryos. | Guo, Q., et al. 2018. Reprod Fertil Dev. 30: 1002-1010. PMID: 29301091
- The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines. | Rødland, GE., et al. 2019. Front Oncol. 9: 1301. PMID: 31850205
- A Novel Strategy for Regulating mRNA's Degradation via Interfering the AUF1's Binding to mRNA. | Li, KT., et al. 2022. Molecules. 27: PMID: 35630659
Inhibitor of:
ARK-1, ARK-2, C-Nap1, Cdc2, Cdc2L5, Cdk2, Cdk3, cyclin A, cyclin B, cyclin B1, cyclin D, cyclin D1, cyclin E, Grid2ip, Kin28, p107, p14 ARF/p16, Speedy A, and String.Activator of:
Plk, and RIOK1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Aurora Kinase/Cdk Inhibitor, 5 mg | sc-203829 | 5 mg | $440.00 |